Concepedia

Liqing Kang

LK

Statistics

Publications

41

Citations

1.3K

H-Index

25

Active since

2017

Affiliations

East China Normal University(Current)

First Affiliated Hospital of Soochow University

Soochow University

Shanghai Genon Biological Products (China)

First Affiliated Hospital of Harbin Medical University

Liqing Kang is an author at East China Normal University specializing in immunotherapy, chimeric antigen receptor t-cell therapy, and oncology.

Publications per year

2017–2024

41

Publications

41

Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden

Changju Qu, Nana Ping, Liqing Kang et al. · Journal of Immunotherapy · 2019 · 94 citations

Medicine, Oncology, Radiation Oncology +17

Anti‐CD19 and anti‐BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem‐cell transplantation for high‐risk newly diagnosed multiple myeloma

Xiaolan Shi, Lingzhi Yan, Jingjing Shang et al. · American Journal of Hematology · 2022 · 79 citations · Full text

Medicine, Hematology, Oncology +17

Interleukin-6-knockdown of chimeric antigen receptor-modified T cells significantly reduces IL-6 release from monocytes

Liqing Kang, Xiaowen Tang, Jian Zhang et al. · Experimental Hematology and Oncology · 2020 · 72 citations · Full text

Life Sciences, Cell Biology, Immunology +17

Nanoengineered Neutrophils as a Cellular Sonosensitizer for Visual Sonodynamic Therapy of Malignant Tumors

Jing‐e Zhou, Tengshuo Luo, Jing Wang et al. · Advanced Materials · 2022 · 70 citations

Pharmacy, Bioengineering, Oncology +17

pPB Peptide-Mediated siRNA-Loaded Stable Nucleic Acid Lipid Nanoparticles on Targeting Therapy of Hepatic Fibrosis

Zongxiang Jia, Yan Gong, Yufang Pi et al. · Molecular Pharmaceutics · 2017 · 63 citations

Pharmacy, Pharmaceutics, Pharmacology +17

1–5 of 41